Platelet transfusion support for patients with cancer and hematologic malignancies

Current Opinion in Hematology

Volumn 3, Issue 5, 1996, Pages 347-354

  Sarkodee Adoo, Clarence ^a   Schiffer, Charles A ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; BACTERIUM CONTAMINATION; BLOOD TRANSFUSION REACTION; CANCER; CYTOMEGALOVIRUS INFECTION; HUMAN; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VIRUS TRANSMISSION;

EID: 0029851547     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603050-00003     Document Type: Review

References (79)

1. Pisciotto PT, Benson K, Hume H, Glassman AB, Oberman H, Popovsky M, Hines D, Anderson K: Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995, 35:498-502. This survey of hospital members of the American Association of Blood Banks collected data by questionnaire for the year 1992. Only 40.4% of the questionnaires were returned, and it is possible that a selection bias may have occurred. Nevertheless the 786 institutions that reported data represent a substantial proportion of US hospitals where patients with hematologic and oncologic disease are treated.
2. Beutler E: Platelet transfusions: the 20,000/μL trigger. Blood 1993, 81:1411-1413.
3. Schiffer C: Prophylactic platelet transfusion. Transfusion 1992, 32:295-298.
4. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A: Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet 1991, 338:1223-1226.
5. Fanning J, Hilgers RD, Murray KP, Bolt K, Aughenbaugh DM: Conservative management of chemotherapeutic-induced thrombocytopenia in women with gynecologic cancers. Gynecol Oncol 1995, 59:191-193. in this study 100 episodes of chemotherapy-induced severe thrombocytopenia (platelet count < 20,000/μL) were evaluated in 46 patients.The threshold for prophylactic transfusions was set at 5000/μL during a part of the study but did not result in significant increases in bleeding complications. This study provides further evidence that in stable patients the threshold for prophylactic transfusion can safely be set at counts lower than 20,000/μL.
6. Dutcher JP, Schiffer CA, Aisner J, Wiernik PH: Long-term follow-up of patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood 1981, 58:1007-1011.
7. Howard JE, Perkins HA: The natural history of alloimmunization to platelets. Transfusion 1978, 18:496.
8. DeCoteau J, Haddad S, Blanchette V, Poon A: Refractoriness to platelet transfusions in children with acute leukemia. J Pediatr Hematol Oncol 1995, 17:306-310. This retrospective study of 213 pediatric patients is the largest report so far of alloimmunization in children with acute leukemia. Alloimmunization occurred in nine of the 31 patients with acute myeloid leukemia (31%), but only three of 133 patients with acute lymphoblastic leukemia (2.3%). The rate of 31% for children with acute myeloid leukemia approximates that reported for adults in other studies.
9. Hogge ED, Dutcher JP, Aisner J, Schiffer CA: Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusions. Am J Hematol 1983, 14:363-369.
10. Nusenzweig MC, Steinman RM Contribution of dendritic cells to stimulation of the murine syngeneic mixed leukocyte reaction. J Exp Med 1980, 151:1196-1198.
11. 11 platelets.
12. 6 leukocytes/product of single-donor, ABO-compatible platelets did not appreciably affect alloimmunization rates among previously pregnant women with hematologic malignancies. Twenty of 46 patients developed anti-HLA antibodies and were equally distributed in both groups. The alloimmunization rate of 44% is similar to that generally reported for patients with acute myeloid leukemia, unselected for pregnancy or previous transfusions.
13. Abou-Elella AA, Camarillo TA, Allen MB, Barclay S, Pierce JA, Holland HK, Wingard JR, Bray RA, Rodey GE, Hillyer CD: Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995, 35:931-935. Exclusively single-donor apheresis platelets were used in this study. All units as well as all erythrocyte units were gamma irradiated and filtered. The study included patients with leukemia, lymphoma, and breast cancer, in almost equal proportions. Alloimmunization rates were low, as measured by lymphocytotoxic antibody. The discussion in this paper includes a summary of the alloimmunization rates found in other studies.
14. Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benney WB, Massing BG: Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transfusion 1995, 35:645-652. One hundred twenty-eight consecutive patients were studied. Alloimmunization occurred in 24%. As in adults, the lymphocytotoxic antibody assay predicted refractoriness to random donor transfusions but good response to HLA-matched units. There was no difference in alloimmunization rates between patients receiv-ing filtered products and those receiving unfiltered products.
15. Williamson LM, Wimperis JZ, Williamson P, Copplestone JA, Gooi HC, Morgenstern GR, Norfolk DR: Bedside filtration of blood products in the prevention of HLA alloimmunization: a prospective randomized study. Alloimmunisation Study Group. Blood 1994, 83:3028-3035.
16. Brand A, Claas FHJ, Voogt PJ, Wasser MNJM, Eernisse JG: Alloimmunization after leukocyte-depleted multiple random donor platelet transfusions. Vox Sang 1988, 54:160-166.
17. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR: Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988, 71:1402-1407.
18. Andreu G, Dewailly J, Leberre C, Quarre MC, Bidet ML, Tardivel R, Devers L, Lam Y, Soreau E, Boccaccio C, Piard N, Bidet JM, Genetet B, Fauchet R: Prevention of HLA immunization with leukocyte-poor packed cells and platelet concentrates obtained by filtration. Blood 1988, 72:964-969.
19. Saarinen UM, Kekomaki R, Siimes MA, Myllyla G: Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990, 75:512-517.
20. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JWN: Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991, 77:201-205.
21. Schiffer CA: Prevention of alloimmunization against platelets. Blood 1991, 77:1-4.
22. Heddle NM, Blajchman MA: The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 1995, 85:603-606. Editorial comment. The necessary data required in order to recommend the routine use of leukodepletion to prevent alloimmunization is still lacking.
23. Heddle NM: The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies. Transfus Med Rev 1994, 8:15-28.
24. Slichter SJ, Deeg HJ, Kennedy MS: Prevention of platelet alloimmunization in dogs with systemic cyclosporine and by UV-irradiation or cyclosporine loading of donor platelets. Blood 1987, 69:414-416.
25. Deeg HJ, Aprile J, Graham TC, Appelbaum FR, Storb R: Ultraviolet irradiation of blood prevents transfusion-induced sensitization and marrow graft rejection in dogs. Blood 1986, 67:537.
26. Grijzenhout MA, Aarts-Riemens MI, de Gruijl FR, van Weelden H, van Prooijen: HCUVB irradiation of human platelet concentrates does not prevent HLA alloimmunization in recipients. Blood 1994, 84:3524-3531.
27. Ten Haaft MA, van den Berg-Loonen PM, van Rhenen DJ: Prevention of primary HLA class I allo-immunization with leucocte-poor blood components produced without the use of platelet filters. Vox Sang 1992, 63:257.
28. Novotny VM, van Doom R, Witvliet MD, Claas FH, Brand A: Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 1995, 85:1736-1741. A prospective study involving 229 patients, of whom 164 were evaluable. Nineteen patients (12%) developed anti-HLA antibodies. This included nine of 25 patients (36%) with a prior history of pregnancy, and three of 112 (2.7%) without any history of previous pregnancy or transfusions.
29. 6 leukocytes after filtration. The efficacy of filtration depended on the prefiltration leukocyte content of the product, an indication that in routine practice filtration may not result in leukodepleted products as infallibly as is suggested in initial studies.
30. Lee EJ, Schiffer CA: Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 1987, 70:1727-1729.
31. Lohrmann HP, Bull MI, Decter JA, Yankee RA, Graw RG: Platelet transfusions from HLA compatible unrelated donors to alloimmunized patients. Ann Intern Med 1974, 80:9-14.
32. Kickler TS, Braine HG, Ness PM, Koester A, Bias W: A radiolabeled antiglobulin test for crossmatching platelet transfusions. Blood 1983, 61:238-242.
33. O'Connell BA, Lee EJ, Rothko K, Hussein MA, Schiffer CA: Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates. Blood 1992, 79:527-531.
34. McFarland JG, Aster RH: Evaluation of four methods for platelet compatibility testing. Blood 1987, 69:1245.
35. Friedberg RC, Donnelly SF, Mintz PD: Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients. Transfusion 1994, 34:215-220.
36. Schiffer CA, Keller C, Dutcher JP, Aisner J, Hogge D, Wiernik PH: Potential HLA-matched platelet donor availability for alloimmunized patients. Transfusion 1983, 23:286-289.
37. Schiffer CA, O'Connell B, Lee EJ: Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets. Blood 1989, 74:1172-1176.
38. Hussein MA, Lee EJ, Fletcher R, Schiffer CA: The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients. Blood 1996, 87:3959-3962.
39. Gharpure VS, Norris D, Lee EJ, Schiffer CA: Use of 'split' plateletpheresis products for alloimmunized patients. Vox Sang 1994, 67:272-274.
40. Schiffer CA, Aisner J, Wiernik PH: Frozen autologous platelet transfusion for patients with leukemia. N Engl J Med 1978, 299:7-12.
41. 9 were obtained from autologous platelets previously harvested from patients with acute meylogenous leukemia who were alloimmunized. Hemorrhage during marrow aplasia was prevented in all patients studied.
42. Salama A, Kiefel V, Mueller-Eckhardt C: Effect of IgG anti-Rho (D) in adult patients with chronic autoimmune thrombocytopenia. Am J Hematol 1986, 22:241.
43. Heddle NM, Klama L, Kelton JG, Meyer R, Walker I, Dickson L, Chambers S, Levine MN: The use of anti-D to improve post-transfusion platelet response: a randomized trial. Br J Haematol 1995, 89:163-168.
44. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZ, Lister TA, Waters AH: Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994, 66:200-205.
45. Bishop JF, McGrath K, Wolf MM, Matthews JP, DeLuise T, Holdsworth R, Yuen K, Veale M, Whiteside MG, Cooper IA, Szer J: Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988, 71:383-387.
46. Lee EJ, Norris D, Schiffer CA Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion 1987, 27:245-247.
47. Chambers LA, Kruskall MS, Pacini DG, Donovan LM: Febrile reactions after platelet transfusion: the effect of single versus multiple donors. Transfusion 1990, 30:219-221.
48. Heddle NM, Klama LN, Griffith L, Roberts R, Shukla G, Kelton JG: A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions. Transfusion 1993, 33:794-797.
49. Heddle NM, Klama L, Singer J, Richards C, Fedak P, Walder I, Keton JG: The role of the plasma from platelet concentrates in transfusion reac-tions. N Engl J Med 1994, 331:625-628.
50. Aye MT, Palmer DS, Giulivi A, Hashemi S: Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion 1995, 35:117-124. Prestorage filtration reduces the accumulation of cytokines in the plasma fraction of stored platelet concentrates prepared by the platelet-rich plasma method.
51. Kluter H, Muller-Steinhardt M, Danzer S, Wilhelm D, Kirchner H: Cytokines in platelet concentrates prepared from pooled buffy coats. Vox Sang 1995, 69:38-43. Platelet concentrates for this study were prepared by the buffy-coat method and pooled prior to storage. There was no increase in cytokine levels with storage.
52. Muylle L, Peetermans ME: Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994, 66:14-17.
53. Oksanen K, Ebeling F, Kekomaki R, Elonen E, Sahlstedt L, Volin L, Myllyla G: Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat Vox Sang 1994, 67:356-361.
54. Goodnough LT, Riddel J IV, Lazarus H, Chafel TL, Prince G, Hendrix D, Yomtovian R: Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration. Vox Sang 1993, 65:103-107.
55. Federowicz I, Barrett BB, Anderson JW, Urashima M, Popovsky MA, Anderson KC: Characterization of reactions after transfusion of cellular blood components that are white cell reduced before storage. Transfusion 1996, 36:21-28.
56. Sweeney JD, Holme S, Stromberg RR, Heaton WA: In vitro and in vivo effects of prestorage filtration of apheresis platelets. Transfusion 1995, 35:125-130.
57. Matthieu F: A very simple and nonexpensive technique to prevent febrile nonhemolytic transfusion reactions in HLA-immunized patients. Vox Sang 1995, 68:201-202.
58. Dzieczkowski JS, Barrett BB, Nester D, Campbell M, Cook J, Sugrue M, Andersen JW, Anderson KC: Characterization of reactions after exclusive transfusion of white cell-reduced cellular blood components. Transfusion 1995, 35:20-25.
59. Chiu EKW, Yuen KY, Lie R, Liang R, Lau YL, Lee ACW, Kwong YL, Wong S, Ng MH, Chan TK: A prospective study of symptomatic bacteremia following platelet transfusion and of its management. Transfusion 1994, 34:950-954.
60. Zaza S, Tokars JI, Yomtovian R, Hirschler NV, Jacobs MR, Lazarus HM, Goodnough LT, Bland LA, Arduino MJ, Jarvis WR: Bacterial contamination of platelets at a university hospital: increased identification due to intensified surveillance. Infect Control Hosp Epidemiol 1994, 15:82-87.
61. Davda RK, Collins KA, Kitchens CS: Case report: fatal Staphylococcus aureus sepsis from single-donor platelet transfusion. Am J Med Sci 1994, 307:340-341.
62. Wagner SJ, Moroff G, Katz AJ, Friedman LI: Comparison of bacteria growth in single and pooled platelet concentrates after deliberate inoculation and storage. Transfusion 1995, 35:298-302.
63. Workman K, Burstain J, Breacher M: Glucometry and the detection of bacterially contaminated platelets. Transfusion 1995, 35:348.
64. Hogman CF, Gong J: Studies of one invasive and two non-invasive methods for detection of bacterial contamination of platelet concentrates. Vox Sang 1994, 67:351-355.
65. Brecher ME, Hogan JJ, Boothe G, Kerr A, McClannan L, Jacobs MR, Yomtovian R, Chongokolwatana V, Tegtmeier G, Henderson S, Pineda A, Hailing V, Kemper M, Kuramato K, Holland PV, Longiaru M: Platelet bacterial contamination and the use of a chemiluminescence-linked universal bacterial ribosomal RNA gene probe. Transfusion 1994, 34:750-755.
66. Lin L, Londe H, Janda JM, Hanson CV, Corash L: Photochemical inactivation of pathogenic bacteria in human platelet concentrates. Blood 1994, 83:2698-2706.
67. Krishnan LAG, Brecher ME: Transfusion-transmitted bacterial infection. Hematol Oncol Clin North Am 1995, 9:167-185.
68. Blajchman MA, Ali AM, Richardson HL: Bacterial contamination of cellular blood components. Vox Sang 1994, 67(suppl 3):25-33.
69. Blajchman MA: Transfusion-associated bacterial sepsis: the phoenix rises again. Transfusion 1994, 34:940-942.
70. Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis WF, Notari EP, Petersen LR: Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995, 333:1721-1725.
71. van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF: Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994, 87:144-147.
72. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplantation. Blood 1995, 86:3598-3603. A prospective randomized trial comparing filtered blood products to cytomegalovirus-seronegative products in the prevention of transfusion-transmitted cytomegalovirus infection after bone marrow transplantation. This large trial, involving 521 patients of whom 502 were evaluable, demonstrated a low risk of cytomegalovirus infection in both arms. Filtration may be effective for the prevention of transfusion-transmitted cytomegalovirus infection.
73. Goodrich RP, Yerram NR, Tay-Goodrich BH, Forster P, Platz MS, Kasturi C, Park SC, Aebischer JN, Rai S, Kulaga L: Selective inactivation of viruses in the presence of human platelets: UV sensitization with psoralen derivatives. Proc Natl Acad Sci U S A 1994, 91:5552-5556.
74. Margolis-Nunno H, Robinson R, Ben-Hur E, Horowitz B: Quencherenhanced specificity of psoralen-photosensitized virus inactivation in platelet concentrates. Transfusion 1994, 34:802-810.
75. Margolis-Nunno H, Robinson R, Ben-Hur E, Chin S, Orme T, Horowitz B: Elimination of potential mutagenicity in platelet concentrates that are virally inactivated with psoralens and ultraviolet A light Transfusion 1995, 35:855-862.
76. Leitman SF: Use of blood cell irradiation in the prevention of post-transfusion graft-versus-host disease. Trans Sci 1989, 10:2219-2232.
77. Sweeney JD, Holme S, Moroff G: Storage of apheresis platelets after gamma radiation. Transfusion 1994, 34:779-783.
78. Lavee J, Shinfeld A, Savion N, Thaler M, Mohr R, Goor DA: Irradiation of fresh whole blood for prevention of transfusion-associated graft-versus-host disease does not impair platelet function and clinical hemostasis after open heart surgery. Vox Sang 1995, 69:104-109.
79. Ohto H, Anderson KC: Posttransfusion graft-versus-host disease in Japanese newborns. Transfusion 1996, 36:117-123.